International Journal of Medicine and Data

Objective To study the effect of metoprolol on chronic heart failure. Methods 100 patients with chronic heart failure treated in our hospital from January 2020 to December 2021 were divided into experimental group and control group according to different treatment methods, and the treatment effect was analyzed. Results before treatment, the indexes of the two groups were compared (P > 0.05); After treatment, the LVEF index, lved index and 6-min walking distance in the experimental group were better than those in the control group (P < 0.05). The LVEF index, LVEDd index and 6-min walking distance in the experimental group were 48.12 ± 0.35 /%, 35.86 ± 1.12/mm and 568.34 ± 44.22 (m); The total incidence of adverse reactions in the experimental group was 3 (6.00%) lower than that in the control group 10 (20.00%), P < 0.05. The incidence of hypotension in the experimental group was 1 (2.00%), the incidence of angioedema was 1 (2.00%), and the incidence of dry cough was 1 (2.00%); The incidence rate of adverse events in the experimental group was 3 (6.00%) lower than that in the control group 11 (22.00%), among which the recurrence rate of heart failure in the experimental group was 1 (2.00%), the rate of malignant arrhythmia was 1 (2.00%), the rate of cardiogenic shock was 1 (2.00%), the rate of cardiogenic mortality was 0 (0.00%), and the rate of readmission was 0 (0.00%), P < 0.05. Conclusion the incidence of chronic heart failure is relatively high, and the probability of death is also relatively high. Metoprolol can significantly improve the cardiac function of patients with chronic heart failure and reduce the mortality of this disease. It has definite curative effect and can be used.

Metoprolol; Chronic heart failure; LVEF index; Lved index; Adverse reaction